Strasbourg, France – As the Society of Robotic Surgery (SRS) 2025 Annual Meeting enters its core agenda phase, Julia Yuan, General Manager of CCRC Medtech, has emerged as the sole regulatory authority from Greater China, captivating global attendees with her deep expertise. After concluding three pivotal discussions on July 16, she is now poised to lead the Telesurgery Closed-Door Summit on July 19—an exclusive gathering of the world’s top surgeons, regulators, and industry leaders to harmonize global remote surgery standards.
Decoding Greater China’s Market Dynamics & Regulatory Landscape
During Plenary Session 2: Medical Device Regulation, Julia Yuan delivered high-impact analyses on regional regulatory frameworks, spotlighting:
-
Market Position: With its vast population, growing healthcare demands, and innovation-friendly policies, Greater China is now the world’s second-largest medical device market. The surgical robotics sector, after years of development, boasts a mature ecosystem where local innovators compete with global giants, maintaining the fastest growth rate globally.
-
Regulatory Nuances: Julia dissected divergent regulations across Mainland China, Hong Kong, and Taiwan, covering:
-
Device classification criteria
-
Clinical evidence requirements
-
Post-market surveillance
Her case-based demonstrations revealed how companies can tailor compliance strategies to each sub-region, with practical takeaways immediately adopted by multinational attendees for market-entry planning.
-
Closed-Door Summit: Shaping the Future of Telesurgery
The July 19 Telesurgery Summit at IRCAD—reserved for global elites—will address cross-border standardization and safety protocols. As a core architect, Julia Yuan will:
-
Co-lead multinational standard harmonization
-
Draft guidelines for cross-jurisdictional liability allocation
Greater China’s Rising Influence
The region’s market vitality and regulatory innovations are now benchmarks for global medtech advancement. “Through precise regulatory navigation and standard alignment, we aim to accelerate patients’ access to cutting-edge therapies,” emphasized Julia Yuan.
Event continues until July 20. Julia’s participation underscores Chinese CROs’ growing expertise and Greater China’s dual ascent in market clout and regulatory leadership for high-end medical devices.
